Observational study on post-COVID-19 complications
IRCM Post-COVID-19 (IPCO) Research Clinic: a Multidisciplinary Approach to Evaluate Short and Long-term Complications of COVID-19
This study is trying to see what long-term health problems people might have after recovering from COVID-19, focusing on adults aged 18 to 100.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 650 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Institut de Recherches Cliniques de Montreal Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT04736732 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to evaluate the short- and long-term end-organ complications associated with COVID-19 in individuals aged 18 to 100 years. It will recruit up to 627 participants, including those with asymptomatic, mild, moderate, or severe COVID-19 infections, and will follow them for 24 months after symptom onset or diagnosis. The study will also establish a biobank for future research and develop predictive models for end-organ complications. Primary endpoints include the development of any end-organ complications plausibly related to COVID-19.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18 and older who have had a confirmed or suspected COVID-19 infection within the last 24 months.
Not a fit: Patients who have never tested positive for COVID-19 and do not have any related symptoms may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of post-COVID-19 complications and improve patient management strategies.
How similar studies have performed: Other studies have shown success in identifying long-term complications of COVID-19, making this approach both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any gender, ≥ 18 years old * Current resident of Quebec * Speaks English or French * Have a personal email (to which to send reminders and questionnaire by email ) AND 1 of the following criteria: • Individuals with at least one COVID-19 positive PCR test, serology or antibody/antigen test in the last 60 months at day of recruitment. In the absence of a positive COVID-19 test, individuals with symptoms consistent with COVID-19 while living with a person who had a confirmed positive PCR, serology or antibody/antigen COVID-19 test in the last 60 months at day of recruitment (epidemiologic link). OR • Individuals who tested negative for COVID-19 while living with a household member who tested positive for COVID-19 or had a close contact with the viral infection in the context of their work, and never had any COVID-19 related symptoms (presumed COVID negative control group). OR • Individuals who don't have any COVID-19 related symptoms actually, have never had tested positive, and have had at least one negative PCR, serology or antibody/antigen COVID-19 test (presumed COVID negative control group). OR • Individuals with an undiagnosed viral infection in the last 60 months at day of recruitment and have persistent symptoms (or not) after the participant has recovered from a viral infection. Exclusion Criteria: * Any participant not deemed appropriate for enrollment according to the PI * Known pregnancy (female will not be automatically screened for pregnancy upon enrollment unless there is a possibility that they might be pregnant)
Where this trial is running
Montreal, Quebec
- Institut de Recherches Cliniques de Montreal — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Emilia Liana Falcone, M.D., Ph.D. — Ircm
- Study coordinator: Emilia Liana Falcone, M.D., Ph.D.
- Email: Emilia.falcone@ircm.qc.ca
- Phone: 514-987-5610
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.